The reiteration of an Overweight rating and a high price target of $815 by a reputable analyst like Louise Chen from Cantor Fitzgerald is likely to instill confidence among investors and could lead to a positive short-term impact on Eli Lilly's stock price. The analyst's endorsement serves as a strong signal of the company's potential for growth and profitability, making it an attractive investment.